[Gemcitabine is an effective single agent for the treatment of advanced biliary tract cancer].
Gemcitabine, a novel nucleoside analogue, has shown broad clinical activity in a variety of malignant tumors and is currently used for the treatments of non-small-cell lung cancer and pancreatic cancer in Japan. Based on the clinical results obtained in the early clinical trials in other locates, the safety profile was also established. Recently, the clinical usefulness of gemcitabine against advanced biliary tract cancer was approved in Japan. This means an important effective drug was developed against a well-known drug-refractory malignant neoplasm in Japan.
Tsukagoshi
Shigeru
S
Tokyo Cooperative Oncology Group.
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine